Trial Profile
Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative Biomarkers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Nivolumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 22 Aug 2023 Planned End Date changed from 31 Jan 2024 to 30 Apr 2024.
- 22 Aug 2023 Planned primary completion date changed from 31 Jan 2024 to 30 Apr 2024.
- 22 Aug 2023 Status changed from recruiting to active, no longer recruiting.